Celgene Corporation / Sutro Biopharma, Inc.

Immuno-Oncology (PD-1/PD-L1 targeted bispecifics & ADCs)

$40.1B Global immune checkpoint inhibitor market 2022 (analyst, retrospective)

Disease Overview

Immuno-oncology uses checkpoint inhibitors (anti-PD-1/PD-L1 antibodies) and engineered biologics to unleash T-cell responses against tumors. By late 2014, the field was rapidly expanding beyond first-generation monospecific antibodies (Keytruda approved Sept 2014, Opdivo approved Dec 2014) toward bispecifics and ADCs that combine checkpoint blockade with tumor-targeting payloads.

Competitive Landscape

At the time of this October 2014 deal, the IO landscape was dominated by emerging anti-PD-1 monoclonal antibodies — Merck's Keytruda (pembrolizumab, FDA approved Sept 2014 in melanoma) and Bristol-Myers Squibb's Opdivo (nivolumab, approved Dec 2014) — followed by anti-PD-L1 candidates from Roche/Genentech (atezolizumab) and AstraZeneca/MedImmune (durvalumab). Celgene was a leader in hematologic malignancies (Revlimid, Pomalyst) but had limited internal IO biologics capability and was actively building IO via partnerships (Bluebird, Agios, Acceleron). The Sutro deal added a differentiated bispecific antibody and homogeneous-DAR ADC capability via the cell-free XpressCF+ platform, allowing systematic screening across PD-1/PD-L1 plus novel checkpoint targets in parallel — a meaningful counter to Roche's and AbbVie's growing ADC franchises. The deal also gave Celgene an exclusive option to acquire Sutro outright, signaling intent to internalize the platform if early candidates validated. By 2017, the partners refocused the original IO collaboration onto four programs including a BCMA-targeting ADC, and Celgene let the buyout option lapse — freeing Sutro to IPO in 2018.